FDA Form 483 Observations: The 15-Day Response

A Form 483 is the list of inspectional observations an FDA investigator leaves with a compounding facility at the close of an on-site inspection under current good manufacturing practice (cGMP) standards. For a compounding pharmacy operating as a registered 503B outsourcing facility, or a 503A pharmacy inspected under FDA's compounding authority, the document can resemble a verdict, though FDA's own guidance treats it as a preliminary step subject to further agency review rather than a final finding. How the facility responds in the days that follow often determines whether the matter closes quietly or advances toward a warning letter, an injunction, or a referral for further investigation. The stakes include the facility's registration status, its payer and wholesaler relationships, and its ability to continue compounding semaglutide and tirzepatide preparations without interruption.

What A Form 483 Represents At The Close Of Inspection

FDA's Form 483 Frequently Asked Questions page states that the observations recorded on a Form 483 reflect the investigator's judgment at the time of inspection and remain subject to review by FDA supervisors and center staff before the agency reaches a compliance determination. That means a facility receiving a 483 has entered a review process, not a finalized enforcement action. The distinction matters for a compounding pharmacy weighing whether its inspection proceeded under 503A or 503B authority, a question addressed in 503A vs 503B: Which Framework Governs Your Compounding, because the applicable framework shapes both the scope of the inspection and the response strategy that follows.

The 15 Business Day Response Window

FDA's March 2026 draft guidance, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, recommends that establishments submit a written response within 15 business days of the Form 483's issuance, with the issuance date itself excluded from the count and federal holidays excluded from the business-day tally. A response filed inside that window generally receives a detailed review before FDA decides on further action. FDA states that it will not ordinarily delay a compliance or enforcement decision to wait for a response filed after the window closes, and for complex findings the guidance recommends submitting at least a written corrective action plan and a proposed timeline within the same 15 business days, even when the full investigation is not yet complete.

The 15 business day window is the last point at which a compounding facility, rather than FDA, controls what happens next.

Corrective Action Evidence FDA Credits

The draft guidance sets out what FDA considers a substantive response. It calls for a root cause analysis conducted with a scientifically justified, risk-based scope, rather than an explanation limited to the specific observation as written. FDA's guidance for outsourcing facilities reflects the same expectation across 503B inspections generally: investigators expect a facility to determine whether a deficiency is an isolated occurrence or reflects a systemic failure across other products, batches, or facility operations. A response that treats a systemic quality-system gap as an isolated event without addressing that broader scope invites closer scrutiny. FDA also expects a corrective and preventive action (CAPA) plan scaled to the risk identified, with defined timelines and deliverables, plus an effectiveness evaluation that goes beyond routine retesting to confirm the correction actually resolved the underlying problem. Facilities that cannot show this level of rigor, or that miss the response window, face a materially higher likelihood that FDA proceeds to a warning letter or other enforcement action.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and outsourcing facilities promptly retain healthcare defense counsel upon receipt of an FDA Form 483 at the close of an inspection. Early legal intervention can protect the facility's rights, ensure the written response is accurate and appropriately scoped, avoid inadvertent admissions that later surface in a warning letter or consent decree, preserve relevant defenses, and allow counsel to communicate with FDA investigators and district office staff on the facility's behalf. Delaying legal representation until after a response has already been drafted, or until the 15 business day window has closed, can significantly affect the outcome of the matter and expose the facility to unnecessary regulatory and enforcement risk.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies and outsourcing facilities through the FDA Form 483 response process, from initial review of the inspectional observations through drafting the written response, coordinating root cause investigations and corrective action plans with quality and regulatory staff, and handling follow-up communication with the FDA district office. If your pharmacy or facility has received a Form 483, contact us for a free, confidential consultation.